Tian Zhang, MD, MHS
@TiansterZhang
I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PATXe
ID:2171015611
02-11-2013 22:06:07
8,1K Tweets
7,6K Followers
963 Following
Follow People
Join our #WomeninRCC webinar on July 17! Grateful to Lynn Schuchter for her time & wisdom. Will also have 3 early career women recap their #ASCO24 presentations.
Thanks Kidney Cancer for organizing!
Register here:
bit.ly/3VofzVm
Patients & physicians together — Laura Esfeller Katie Coleman Dena Battle — you are the real heroes advocating for patients here w/ us & those who have left our 🌍. We do what we do because of you.
Awesome we now have survivors in #kidneycancer to lend 1st hand advocacy. 💖
Was fortunate to be a small part of #ASCO24 with ⭐️ Jarushka Naidoo Tian Zhang, MD, MHS Melina Marmarelis Charu Aggarwal, MD, MPH, FASCO Patrick Forde Lecia Sequist, MD, MPH and many others including @asco leadership. Looking forward to next year under Dr. Zon ASCOPres and Erika Hamilton, MD!
Always eloquent from the man/the legend Toni Choueiri, MD — #kidneycancer biomarkers from #CLEAR ASCO #ASCO24
Dear Colleagues at #ASCO24
An honor to introduce our OncoAlert 🚨faculty and Heart and Soul of the Network Toni Choueiri, MD 🇺🇸of Dana-Farber who discusses Biomarker Analysis of CLEAR trial in #KidneyCancer
Sumanta K. Pal, MD, FASCO Cristiane D Bergerot Daniel Heng Andrea Apolo, M.D. Toni Choueiri, MD Petros Grivas
Fantastic presentation by Dr. Shilpa Gupta 👉pts reported outcomes from ph3 EV-302 trial ASCO #ASCO24 👉Rx with enfortumab+pembro significantly improved OS without adversely affecting QOL, pain or functioning. Tom Powles Bladder Cancer Advocacy Network OncoAlert Umang Swami
Better results with ipi/nivo in biomarker selected population of #prostatecancer . 40% response but also 40% grade 3+ diarrhea with higher dose ipi. Zang et al reported 50% response with pembro in hi TMB (JAMA Onc 2024). ICI clearly benefits select pts w/mCRPC
Excited to see you take on the scientific planning committee leadership for next year’s meeting, Erika Hamilton, MD!!
Masterful presentation by Shilpa Gupta discussing patient-reported outcomes phase III trial of EV+P vs. PBC in untreated la/mUC:
Patients in the EV+P group have improved survival compared with PBC without detriment to GHS/QoL, pain, or functioning!
Tom Powles Cleveland Clinic